Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for Total Knee Arthroplasty (TKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with an American Society of Anesthesiologists (ASA) physiological status I-III~2. Patients presenting for unilateral primary total knee replacement.~3. No focal neurologic deficit of the surgical lower extremity.~4. Cognitively intact with the ability to sign informed consent~Exclusion Criteria:~1. Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome~2. History of long term use of daily opioids (\>1 months) with oral morphine equivalent (OME) \>5mg/day.~3. Body mass index (BMI) \> 40 kg/m2~4. Allergies to medications used in this study such as: fentanyl, hydromorphone, ketorolac, ibuprofen, acetaminophen, local anesthetics, oxycodone, OxyContin, tramadol, ondansetron, droperidol, or dexamethasone, celecoxib~5. Major systemic medical problems such as:~   * Severe renal disorder defined as glomerular filtration rate (GFR) \<50 units/m2~  * Cardiovascular disorders defined as congestive heart failure (CHF) New York Heart Association (NYHA) class III-IV~  * Severe hepatic disorder defined as current or past diagnosis of acute/subacute necrosis liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), fatty liver, chronic hepatitis/toxic hepatitis, liver abscess, hepatic coma, hepatorenal syndrome, other disorders of liver.~6. Impaired cognitive function or inability to understand the study protocol~7. Contraindication to a regional anesthesia technique (e.g., preexisting neuropathy in the operative extremity, coagulopathy \[platelets \< 100,000, International Normalized Ratio (INR) \>1.5\], refusal, etc.).~8. Previous contralateral knee replacement managed with regional or periarticular injection~9. Unable to follow-up at the 3 month interval at Mayo Clinic in Rochester, Minnesota~10. Pregnancy or breast feeding (women of child-bearing potential, must have a negative pregnancy test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Peripheral Nerve Block (PNB) (Type: ACTIVE_COMPARATOR): This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
- Ropivacaine (PAI-R) (Type: ACTIVE_COMPARATOR): This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
- Liposomal Bupivacaine (PAI-L) (Type: ACTIVE_COMPARATOR): This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).